Korro Bio, Inc.

Item 5. Other Information.

During the three months ended June 30, 2026, the following officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted, amended or terminated contracts, instructions or written plans for the purchase or sale of our securities that were intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act (each, a “Rule 10b5-1 plan”): On May 28, 2026, Loïc Vincent, our Chief Scientific Officer, terminated a Rule 10b5-1 plan providing for the potential sale of up to 7,292 shares of our common stock issuable upon the exercise of stock options, andon June 7, 2026, Dr. Vincent adopted a Rule 10b5-1 plan providing for the potential sale of up to 21,715 shares of our common stock issuable upon the vesting and settlement of restricted stock units, as well as up to 4,584 shares of our common stock issuable upon the exercise of stock options; this plan is scheduled to expire on February 1, 2028. On June 8, 2026, Oliver Dolan, our Senior Vice President, Finance, adopted a Rule 10b5-1 plan providing for the potential sale of up to 21,482 shares of our common stock issuable upon the vesting and settlement of restricted stock units; this plan is scheduled to expire on June 4, 2027. During the three months ended June 30, 2026, none of our other officers or directors informed us that they adopted, modified orterminated a Rule 10b5-1 plan or a trading plan not intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.